A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a non-hemophiliac state

双特异性抗体 抗体 凝结 免疫球蛋白轻链 体外 化学 医学 药理学 免疫学 内科学 单克隆抗体 生物化学
作者
Yuri Teranishi-Ikawa,Tetsuhiro Soeda,Hikaru Koga,Kazuki Yamaguchi,Kazúo Kato,Keiko Esaki,Kentaro Asanuma,Miho Funaki,Mina Ichiki,Yuri Ikuta,Shunsuke Ito,Eri Joyashiki,Shunichiro Komatsu,Atsushi Muto,K. Nishimura,Momoko Okuda,Hisakazu Sanada,Motohiko Sato,Norihito Shibahara,Tetsuya Wakabayashi,Koji Yamaguchi,Akiko Matsusaki,Zenjiro Sampei,Hirotake Shiraiwa,Hiroko Konishi,Yojiro Kawabe,Kunihiro Hattori,Takio Kitazawa,Tomoyuki Igawa
标识
DOI:10.1101/2022.12.19.520692
摘要

Abstract Emicizumab, a factor (F)VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment for people with hemophilia A (PwHA). Although emicizumab is very potent, long-term outcomes from the clinical studies suggest that a small proportion of PwHA still experiences bleeds. Additionally, non-clinical studies indicate that the maximum cofactor activity of emicizumab is lower than international standard activity (100 IU/dL of FVIII). An increased cofactor activity BsAb would benefit such patients. Here, we report NXT007, a BsAb binding FIXa and FX developed through further engineering of emicizumab. Emicizumab has a common light chain, but through advances in antibody engineering, we were able to create a more potent BsAb with two new non-common light chains. After extensive optimization of the heavy and light chains, the resulting BsAb, NXT007, exerted in vitro thrombin generation (TG) activity in hemophilia A plasma equivalent to 100 IU/dL of FVIII when triggered by tissue factor. NXT007 demonstrated potent hemostatic activity in an acquired hemophilia A model in non-human primates at a much lower dosage than emicizumab, consistent with an around 30-fold dose shift in the in vitro TG activity between NXT007 and emicizumab. Moreover, together with Fc engineering that enhanced FcRn binding and reduced in vivo clearance, we demonstrate that NXT007 could be effective at a much lower dosage with a longer dosing interval compared to emicizumab. These non-clinical results suggest that NXT007 could maintain a non-hemophilic range of coagulation potential in PwHA and provides a rationale for its clinical testing.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
huoyunli发布了新的文献求助10
刚刚
Pidan完成签到,获得积分10
刚刚
李露露完成签到 ,获得积分10
1秒前
CodeCraft应助sylnd126采纳,获得10
1秒前
碳烤小肥肠完成签到,获得积分10
2秒前
夌隺完成签到,获得积分10
2秒前
木卫三完成签到,获得积分10
3秒前
哈基米完成签到 ,获得积分20
3秒前
鱼饼完成签到 ,获得积分10
3秒前
合适怡完成签到,获得积分10
3秒前
夜已深完成签到,获得积分10
3秒前
安静的从安完成签到,获得积分10
4秒前
健忘的芷荷完成签到,获得积分10
4秒前
4秒前
Banbor2021完成签到,获得积分0
5秒前
hzhang完成签到,获得积分10
5秒前
5秒前
yummy完成签到,获得积分10
6秒前
SA发布了新的文献求助30
6秒前
KVBVB完成签到,获得积分10
6秒前
6秒前
奋斗的若云完成签到,获得积分10
6秒前
小悦悦完成签到 ,获得积分10
7秒前
7秒前
zsyzxb完成签到,获得积分10
7秒前
LI完成签到,获得积分10
8秒前
8秒前
Liar完成签到,获得积分10
8秒前
知123完成签到,获得积分10
8秒前
way完成签到,获得积分10
9秒前
小二郎应助gdh采纳,获得10
9秒前
lyp7028发布了新的文献求助10
9秒前
无辜访彤发布了新的文献求助10
10秒前
10秒前
英俊的铭应助miemie阳采纳,获得10
10秒前
一叶知秋完成签到,获得积分10
12秒前
胡杨完成签到,获得积分10
12秒前
思源应助刘宇采纳,获得10
12秒前
bind发布了新的文献求助10
12秒前
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968719
求助须知:如何正确求助?哪些是违规求助? 3513608
关于积分的说明 11168681
捐赠科研通 3248960
什么是DOI,文献DOI怎么找? 1794573
邀请新用户注册赠送积分活动 875194
科研通“疑难数据库(出版商)”最低求助积分说明 804716